Home

Articles from Nuvectis Pharma, Inc.

Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
Fort Lee, NJ, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · December 10, 2024
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
By Nuvectis Pharma, Inc. · Via GlobeNewswire · November 14, 2024
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics
Fort Lee, NJ, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming scientific presentations for NXP900 at the 2024 AACR-NCI-EORTC on Molecular Targets and Cancer Therapeutics (October 23-25, 2024, Barcelona, Spain).
By Nuvectis Pharma, Inc. · Via GlobeNewswire · October 23, 2024
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Fort Lee, NJ , Oct. 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference taking place on October 9, 2024 in New York, NY.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · October 7, 2024
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Fort Lee, NJ, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · September 5, 2024
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
Fort Lee, NJ, May 16, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 2nd BioConnect Investor Conference at the NASDAQ world headquarters in New York City.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · May 16, 2024
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
By Nuvectis Pharma, Inc. · Via GlobeNewswire · April 8, 2024
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP800 and NXP900 at the upcoming 2024 American Association for Cancer Research Meeting (2024 AACR), taking place from April 5th to April 10th in San Diego, California. Presentation details are below:
By Nuvectis Pharma, Inc. · Via GlobeNewswire · March 19, 2024
Nuvectis Pharma to Present at the 36th Annual Roth Conference
FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 36th Annual Roth Conference.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · March 15, 2024
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
By Nuvectis Pharma, Inc. · Via GlobeNewswire · March 14, 2024
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:
By Nuvectis Pharma, Inc. · Via GlobeNewswire · February 9, 2024
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:
By Nuvectis Pharma, Inc. · Via GlobeNewswire · February 9, 2024
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 42nd Annual J.P. Morgan Healthcare Conference, as follows:
By Nuvectis Pharma, Inc. · Via GlobeNewswire · January 3, 2024
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
By Nuvectis Pharma, Inc. · Via GlobeNewswire · December 18, 2023
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
Fort Lee, NJ, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced an upcoming scientific presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer (November 16-18, 2023, Boston, MA).
By Nuvectis Pharma, Inc. · Via GlobeNewswire · October 24, 2023
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 2023 Cantor Global Healthcare Conference Corporate Presentation, as follows:
By Nuvectis Pharma, Inc. · Via GlobeNewswire · September 25, 2023
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming scientific presentations for NXP800 at the 2023 AACR Special Conference In Cancer Research: Ovarian Cancer (October 5-7, 2023, Boston, MA) and for NXP800 and NXP900 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (October 11-15, 2023 Boston, MA).
By Nuvectis Pharma, Inc. · Via GlobeNewswire · September 21, 2023
Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial
Fort Lee, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of a Phase 1a dose escalation clinical trial of NXP900, its novel inhibitor of the SRC/YES1 kinase family (“SFK”). The study is designed to evaluate the safety, tolerability and pharmacokinetic properties of NXP900 in patients with advanced solid tumors.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · September 12, 2023
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ET
By Nuvectis Pharma, Inc. · Via GlobeNewswire · September 6, 2023
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Fort Lee, NJ, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:
By Nuvectis Pharma, Inc. · Via GlobeNewswire · September 1, 2023
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma
Fort Lee, NJ, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that NXP800 was granted Orphan Drug Designation by the United States Food and Drug Administration (“FDA”) for the treatment of cholangiocarcinoma.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · August 17, 2023
Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
Fort Lee, NJ , June 20, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that it will be added to the Russell 2000® and Russell 3000® Indexes as part of the 2023 Russell indexes reconstitution, according to a preliminary list of additions posted May 19, and effective upon the U.S. market close on June 23, 2023.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · June 20, 2023
Nuvectis Pharma Announces FDA Clearance of NXP900 IND
Fort Lee, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food and Drug Administration (“FDA”) cleared the Company's Investigational New Drug Application (“IND”) for NXP900, which includes the Phase 1 clinical trial protocol.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · May 15, 2023
Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) -- In the news release, Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference, please note that the conference date is May 2nd, 2023.  The complete, corrected release follows: 
By Nuvectis Pharma, Inc. · Via GlobeNewswire · April 27, 2023
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ world headquarters in New York City.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · April 27, 2023
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting
Fort Lee, NJ, April 18, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today provided highlights from the poster presentation of NXP800 that took place yesterday at the American Association for Cancer Research (“AACR”) Annual Meeting 2023 in Orlando, FL (to view the poster, titled Inhibition of HSF1 Demonstrates Therapeutic Efficacy in Preclinical PDX Models of Human Cholangiocarcinoma, click here).
By Nuvectis Pharma, Inc. · Via GlobeNewswire · April 18, 2023
Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma
Phase 1b study builds on highly consistent preclinical and Phase 1a data
By Nuvectis Pharma, Inc. · Via GlobeNewswire · April 10, 2023
Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting
Fort Lee, NJ, March 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP800 and NXP900 at the upcoming 2023 American Association for Cancer Research Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida. Presentation details are below:
By Nuvectis Pharma, Inc. · Via GlobeNewswire · March 17, 2023
Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference
FORT LEE, NJ, March 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · March 10, 2023
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress
Treatment with NXP800 resulted in substantial tumor growth inhibition in two in vivo xenograft models of ARID1a-mutated ovarian carcinoma, superior to treatment with cisplatin
By Nuvectis Pharma, Inc. · Via GlobeNewswire · February 23, 2023
Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States
Dr. Susana Banerjee (The Royal Marsden NHS Foundation Trust, UK), will be the ENGOT and Global Clinical Trial Lead
By Nuvectis Pharma, Inc. · Via GlobeNewswire · January 4, 2023
FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQNVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Fast Track Designation to NXP800 for the treatment of platinum-resistant, ARID1A-mutated ovarian carcinoma.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · December 1, 2022
Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
FORT LEE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company’s management team will participate at the Roth Inaugural Healthcare Opportunities Conference.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · October 3, 2022
Nuvectis Pharma Announces Formation of a Scientific Advisory Board
FORT LEE, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the formation of a Scientific Advisory Board (“SAB”) comprised of world-renowned experts in translational science and clinical research that will help guide the Company’s research and development strategy. 
By Nuvectis Pharma, Inc. · Via GlobeNewswire · September 28, 2022
Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement
Fort Lee, NJ, July 27, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, announced today that it has entered into definitive agreements with healthcare-focused institutional and accredited investors for the issuance and sale of 1,924,689 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $8.25 per share and preferred investment option. The investors also purchased preferred investment options to purchase up to an aggregate of 1,924,689 shares of common stock. The preferred investment options will have an exercise price of $9.65, will become exercisable commencing six months following date of issuance and will have a term of three and one-half years from the date of issuance.
By Nuvectis Pharma, Inc. · Via GlobeNewswire · July 27, 2022